SHIVOM ECOSYSTEM BLOCKCHAIN PLATFORM

A unique and powering Project, Shivom will enable DNA data donors to collaborate with revolutionary changemakers in biotechnology, healthcare industry, and government-ordained research institutes and contribute to an unprecedented era of medical marvels.

SHIVOM ECOSYSTEM.
Shivom is creating a genomics ecosystem the blockchain. We will offer an open marketplace for healthcare providers to add their apps and services, alongside genomic data analytics and personalized medicine shivom blockchain platform.

VISION & VALUES.
Every body one of the 7.6 billion people on earth has a unique code held within their genes that unlocks the secrets to appearance, ancestry, intellectual capabilities, health, and fitness. But, this code’s ability to reveal predisposition to disease has been overlooked.

Improve global health.
Now is the time for concerted, community wide development for the “Demonical” challenges of the coming decade. Currently, a few key players hold the monopoly on genomic data and make huge profits from selling it to 3rd parties, usually without sharing the earnings with the data donor.
We are at the forefront of data security. We use state of the art cryptography to add additional security levels to our platform that go well beyond blockchain technology for decentralization,

GLOBAL LEADERSHIP.
Shivom’s international team harnesses a wealth of cross-sector experience, skills and perspectives that come together around a common vision for Shivom and the democratization of the healthcare industry. The team shares a genuine optimism for the future, entrepreneurial drive and the passionate belief that Shivom will herald the next era of genomics and precision medicine and be a powerful force for positive social impact and good globally.

FOUNDING MEMBERS

DR. AXEL SCHUMACHER
CO-FOUNDER & CEO

Axel has over 20 years of R&D leadership experience in genomics, epigenetics, biomarker discovery, Bio-IT, and aging & longevity. He is the Author of the ‘Blockchain & Healthcare Strategy Guide’, the standard compendium for the healthcare industry. Axel translates scientific discoveries into practical applications to help understand, diagnose, and treat complex disorders, but also to promote cutting-edge technologies that could transform precision medicine and the way we age. Axel is a Faculty-Member of the Blockchain Research Institute in Toronto. He holds a PhD in Human Genetics from the University of Cologne.

GOURISH SINGLA
CO-FOUNDER & COO

SALLY EAVES
CO-FOUNDER & CMO

SHIVOM INNOVATION COUNCIL

TAAVI RÕIVAS

INVESTORS

With recent technological advancements, evolving patient needs and increasingly outdated business models, both the pharmaceutical industry and global healthcare systems are under intense pressure to innovate via increased R&D efforts, acquisitions and / or new partnerships with cutting-edge companies. Public and private healthcare systems have already been facing revenue pressures and declining margins

For public health, genomics matters significantly. In addition to helping to identify rare diseases, more importantly, genomics also plays a role in 9 of the 10 leading causes of death including heart disease, cancer, Alzheimer’s disease, diabetes and stroke12. These are complex diseases with potentially multiple genetic interplays taking place alongside significant epigenetic risk factors. Treatments for these diseases have been elusive and many patients are non responders. With genome sequencing, it will be possible to tailor treatments for patients based on their genetic backgrounds thereby allowing for more targeted treatment options and increased success rates. Routine genome sequencing of sick and healthy individuals will lead to the discovery of clinically relevant and actionable information. In the future, the number of conditions which have treatments or can be prevented based on genomic data will increase
dramatically. The importance of genome-based companion diagnostics or Companion diagnostic tests (CoDx), which define the subset of patients who are most likely to benefit from a therapy or who should not receive the therapy because of ineffectiveness or predicted adverse effects, will increase significantly too.

Internet of Things Data (IOTA Tangle): IOTA is different from how a classical global blockchain works given its use of a directed acyclic graph (DAG), aka a Tangle. The transactions issued by nodes (entities that issue transactions) constitute the site set of the tangle (i.e., the tangle graph is the ledger for storing transactions). Sites are transactions represented on the tangle graph. To send an IOTA transaction, a user’s device must simply confirm two other transactions on the Tangle (the network) via low difficulty “proof of work” math problem computations. This removes the need to waste
large quantities of energy on mining or risk inevitable validation centralization.

Join Website: https://shivom.io/
MyEther Wallet: 0x5B1215dfED1cdCf32d9c860F591180E236D2aba3